Board of Directors
M. Ann Abbe
Mathew Bergman, Esq.
Robert B. Cameron, M.D.
Michael Harbut, M.D., M.P.H.
Ulf Jungnelius, M.D.
Susan Vento
Nicholas J. Vogelzang, M.D.
Mouzetta Zumwalt-Weathers
Roger G. Worthington, Esq.
In Memoriam
Congressman Bruce F. Vento
Bill Powell
Science Advisory Board
Steven Albelda, M.D.
Raphael Bueno, M.D.
Raffit Hassan, M.D.
Steve Hahn, M.D.
Hedy Lee Kindler, M.D.
Dan Miller, M.D.
Harvey Pass, M.D., Chairman
Lary A. Robinson, M.D.
Victor Roggli, M.D.
W. Roy Smythe, M.D.
Robert N. Taub, M.D.
Joseph R. Testa, Ph.D.
Eric Vallieres, M.D.
Claire Verschraegen, M.D.
Executive Director
Christopher E. Hahn
MARF, inc.
1123 Chapala Street
2nd Floor
PO Box 91840
Santa Barbara, CA 93190-1840
tel: (805) 560-8942
fax: (805) 560-8962
http://www.marf.org
|
Our Mission is to eradicate mesothelioma as a
life-ending disease.
VIA E-MAIL, TELECOPY, and U.S. MAIL
January 21, 2005
The Honorable Arlen Specter
Chairman, Senate Judiciary Committee
711 Hart Building
Washington, D.C. 20510
Re: Solution to Asbestos Public Health
Crisis
Dear Senator Specter:
As you have acknowledged, asbestos disease in this country
is a public health crisis. We the undersigned are doctors
and scientists who have expertise in the diagnosis,
causation, prevention and treatment of malignant
mesothelioma, the signature cancer for asbestos exposure.
Mesothelioma is painful tumor with a dismal prognosis, and
our mission is to increase the funding of the medical
research that will, we believe, eventually solve the
problem.
On January 11, 2005, Billy Speicher, a mesothelioma
patient, implored his government to help find a cure. We
were pleased that in response you acknowledged that
asbestos disease is more than a litigation crisis and that
the government should play a leadership role in funding
medical research. You indicated that you, as a member of
the Labor-HHS subcommittee, would look into how much of the
National Cancer Institute's nearly $5 billion budget is
earmarked for basic and applied research on mesothelioma.
We also looked into this question, and here is what we
found. From 2000 to 2003, the NCI spent on average $2.1
million per year on grants which use the word
"mesothelioma" in their abstract. This amount is
far less than .1% of the NCI's 2004 budget. Unlike
other cancers, the NCI does not even have a formal budget
for mesothelioma research, nor does it solicit grants
relating to the treatment or cure of mesothelioma.
Mesothelioma kills between 3,000 and 4,000 Americans
annually (the exact number is unknown since this country
does not have a nationwide registry unlike many others).
Cervical cancer, which has a similar mortality profile
(viz., about 4,100 deaths per year), in 2003 received $71.3
million from the NCI. To put those numbers into
perspective, the NCI allocated $17,340 for each cervical
cancer death, but only $933 per mesothelioma death.
Clearly, mesothelioma is under-funded when compared to
other cancers.
Of the patients diagnosed with mesothelioma every year,
approximately 32% were exposed to asbestos while serving in
the U.S. Navy or while working in U.S. Navy shipyards.
However, neither the Department of Defense nor the
Department of Veterans Affairs has a program for the
detection, prevention, treatment or cure for mesothelioma.
Meanwhile, Congress has since 1992 appropriated over $3.4
billion to the DOD for Congressionally Directed Medical
Research Programs (CDMRPs). A substantial portion of those
billions has been targeted for breast, ovarian and prostate
cancer research -- cancers that are not specific to
military service. Mesothelioma, on the other hand, is
clearly a service-connected injury for veterans who worked
with and around asbestos.
We believe the Federal Government must take the lead in
solving the national tragedy of mesothelioma. Mesothelioma
has been a known occupational cancer for over 50 years.
Billions of dollars have been consumed by asbestos
litigation, most of which has been absorbed by transaction
costs. Thousands of veterans and civilians have already
died as a result of asbestos diseases, and the mortality
rate for asbestos cancers is expected to climb over the
next 10 years, as millions of tons of asbestos remain in
place in schools, buildings, homes and workplaces
throughout the country, subjecting millions of Americans to
an increased risk of cancer. The asbestos epidemic will
continue to haunt us for decades, unless we take long
overdue curative action.
In 2002, MARF proposed a comprehensive $140 million
mesothelioma research and treatment program, which is 0.1%
of the projected value of the $140 billion federal
asbestos trust fund you are endorsing. The program
addresses the public health program at all levels:
prevention, early detection, education, treatment and cure.
The program would foster collaboration between public and
private researchers, create nationwide treatment networks,
promote and fund innovative research, attract top
scientific and medical talent, and provide meaningful
treatment options. In particular, the program would:
-
Establish a competitive peer review grant program;
-
Fund Ten (10) Centers of Mesothelioma
Research/Treatment Excellence ($2.5M per year for five
(5) years);
-
Fund the Admiral Elmo Zumwalt Registry and Clinical
Database;
-
Fund the Congressman Bruce Vento Blood & Tissue
Bank; and
-
Target Research Priorities, which include:
- Biomarkers for early detection and prediction of
recurrence;
- Biological therapies (immunotherapy, gene therapy,
novel chemotherapeutic compounds);
- Strategies for prevention (inhibit pathways
transforming normal to malignant cells); and
- Pain Management (mesothelioma is an extremely
aggressive and painful tumor).
The current version of the FAIR bill incorporates only a
portion of MARF's proposal. Unfortunately, the need to
fund medical research has always been drowned out by the
often shrill debate over who pays and how much. Because
asbestos disease is a public health crisis, and because the
U.S. Government must play a leadership role in solving the
health problem, we believe present and future asbestos
disease patients are best served by a direct appropriation
for a CDMRP for mesothelioma. The need to alleviate the
suffering, extend survival, prevent needless death and
create hope should not be tied to the fortunes of an
asbestos litigation reform bill, which historically has
failed to resonate with the American people in general and
asbestos victims in particular. Compensating victims does
not in itself solve the health crisis, and the two issues
should be treated separately.
The U.S. Government has a role and so does industry, which
for years mined, milled and processed the once ubiquitous
mineral fiber. As you have said repeatedly, since 2000,
over 40 former asbestos companies have sought
reorganization under Chapter 11 of the Bankruptcy Code.
Experts project that the aggregate value of all pending
asbestos debtors' settlement trusts will exceed $65
billion (this number does not include the value of the
10-15 existing Chapter 11 asbestos debtor trusts). A
substantial portion of the future trusts will be siphoned
off by management fees. Yet none of that money is required
to be set aside for peer-reviewed competitive research
grants to help alleviate the suffering of current claimants
or extend the lives of future claimants. We implore
Congress to amend the Bankruptcy Code to mandate that a
reasonable percentage of existing and future asbestos
settlement trusts be allocated to a medical research trust,
which will target and fund meritorious research programs
designed to detect, prevent, treat and cure asbestos
cancers. The former asbestos companies will walk away from
the bankruptcy courts, cleansed of their tort liabilities,
and leave behind a legacy of 27 million Americans with
dangerous levels of carcinogenic asbestos fibers in their
lungs, fibers which one day may generate lung cancer or
mesothelioma, for which the median survival at present is
12.3 months for those patients fortunate enough to qualify
for chemotherapy.
We believe we can find the Achilles heel in mesothelioma.
Even with limited funding, we have been able to make
meaningful improvements in the survival of mesothelioma
patients. But to declare victory against this terrible
tumor which has exacted such a heavy toll on Navy veterans,
and which over the next 15 years will likely rear its ugly
head in the lung and abdominal linings of the brave men and
women who responded to the 9/11 terrorist attack at Ground
Zero, we cannot continue to rely on private donations
alone. We need the resources and the commitment of the U.S.
Government. The Government has the awesome power to replace
despair with hope, nihilism with optimism, defeatism with a
can-do spirit, and rhetoric with action.
We appreciate your efforts to help our
patients survive the ravages of a tumor that does not
respect rank, power, age, sex, fame or political
affiliations. We would be pleased to meet with you and your
staff to articulate the details underlying MARF's
proposals.
Sincerely,
Steven Albelda, M.D.
Vice Chief and Director, Lung Research
University of Pennsylvania
Philadelphia, Pennsylvania |
Raphael Bueno, M.D.
Division of Thoracic
Surgery
Brigham & Womens Hospital
Boston, Massachusetts |
Robert B. Cameron, M.D.
Associate Professor of
Clinical Surgery
UCLA Medical Center
Los Angeles, California |
| |
|
|
Steve Hahn, M.D.
Department of Radiation
Oncology
Philadelphia, Pennsylvania |
Michael Harbut, M.D.
Center for Occupational
and
Environmental Medicine
Royal Oak, Michigan |
Hedy Lee Kindler, M.D.
University of Chicago
Medical Center
Section of
Hematology/Oncology
Chicago,
Illinois |
| |
|
|
Ulf Jungnelius, M.D
Pfizer, Inc
Executive Director
Oncology Clinical Development
New London, Connecticut |
Dan Miller, M.D.
Surgical Director,
Thoracic Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia |
Harvey Pass, M.D.
Professor of Surgery
and Oncology
Karmanos Cancer
Institute
Detroit, Michigan |
| |
|
|
Lary A. Robinson, M.D.
Director, Div. of
Cardiovascular &
Thoracic Surgery
H. Lee Moffitt Cancer Center &
Research Institute |
Victor Roggli, M.D.
Professor of Pathology,
Duke University
and Virginia Medical Centers
Durham VA Medical Center
Durham, North Carolina |
W. Roy Smythe, M.D.
Professor &
Chairman
Texas A&M Univ.
Health Sciences Ctr.
Scott & White
Hospital and Clinic
Department of Surgery
Temple, Texas |
| |
|
|
Daniel Sterman, M.D.*
Director, Interventional
Pulmonology Program
Clinical Director, Thoracic Oncology Gene
Therapy Program
Associate Professor of
Medicine in Surgery
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania |
Joseph R. Testa, M.D.
Cancer Genetisist
Fox Chase Cancer Center
Philadelphia, Pennsylvania |
Eric Vallieres, M.D
Thoracic Oncology
Swedish Cancer Institute
Seattle,
Washington |
| |
|
|
Claire Verschraegen, M.D.
Director of Experimental
Therapeutics
Cancer Research and Treatment Center
University of New
Mexico
Albuquerque, New Mexico |
Nicholas J. Vogelzang, M.D.
Director, Nevada
Cancer Institute
Las Vegas, Nevada |
Bret Williams, M.D.
Mesothelioma Patient
Hillsborough, North Carolina |
* President, International Mesothelioma
Interest Group, http://www.imig.org. The
International Mesothelioma Interest Group (IMIG) is a
multinational scientific organization composed of
researchers, clinicians and others dedicated to research
into the causes and cures for Malignant
Mesothelioma.
|
Cc: |
Senate Judiciary
Committee: |
|
|
| |
Sen. Saxby Chambliss (R-GA)
Sen. John Cornyn (R-TX)
Sen. Larry Craig (R-ID)
Sen. Mike DeWine (R- OH)
Sen. Lindsey Graham (R-SC)
Sen. Charles E. Grassley (R-IA)
Sen. Jon Kyl (R-AZ)
Sen. Jeff Sessions (R-AL) |
|
Sen. Patrick J. Leahy, Ranking
Democratic Member, VT
Sen. Joseph R. Biden, Jr. (D-DE)
Sen. Richard J. Durbin (D-IL)
Sen. Russell D. Feingold (D-WI)
Sen. Dianne Feinstein (D-CA)
Sen. Edward M. Kennedy (D-MA)
Sen. Herbert Kohl (D-WI)
Sen. Charles E. Schumer (D-NY) |
| |
Sen. Harry Reid (D-NV)
Sen. Patty Murray (D-WA) |
|
|
|